What is the Parkinson Study Group (PSG)?

The Parkinson Study Group (PSG) is a non-profit group of physicians and other health care providers from medical centers in the United States, Canada and Puerto Rico experienced in the care of Parkinson patients and dedicated to clinical research of Parkinson disease. The PSG was formed in 1986, prompted by the recognition that clinical research in Parkinson disease (PD) required the participation of large numbers of research patients (subjects) under the cooperative care of skilled and experienced research physicians.

Learn more by downloading our informational brochure here.

The PSG aims to advance knowledge about the cause(s), disease progression and treatment of PD and related disorders. The PSG is committed to:

  • open communication within the scientific community;
  • ensuring research is peer reviewed by other health care providers prior to publication and that all research results are available to the public;
  • revealing potential conflicts of interest of the group and each PSG member and;
  • democratic governance of its organizations and activities.

PSG Executive Committee

The PSG is governed by a Constitution and an elected Executive Committee that is primarily responsible for the direction and oversight of its research projects and activities.

EXECUTIVE COMMITTEE OVERVIEW

The PSG Executive Committee oversees all the PSG study steering committees, the Scientific Review Committee, the Mentoring Committee, the Nominating Committee, the Credentials Committee, the Publications Committee, the Standards Committee, the Study Budget Committee, and the Symposia Committee. (Click here to view/download the PSG Standing Committee Members list.) The Executive Committee is also responsible for overseeing the PSG working groups (Atypical Parkinsonian Disorders, Cognitive/Psychiatric (Behavior), Biomarkers, Genetics and Environmental Risk, Health/Care Outcomes and Disparities, Other Non-Motor Features of PD, Functional Neurosurgical and Motor Features of PD) that are responsible for developing new PSG projects. PSG members interested in joining a working group may contact the Chair of that group.

Key Documents

Click below to view/download PDF documents:

PSG Bylaws
PSG Policies & Procedures
Conflict of Interest Guidelines

Click here to download the Executive Committee position statement.

Click here to download the Standing Committee list

Executive Committee Members

MICHAEL SCHWARZCIHLD, MD, PHD, CHAIR (2018-2024)

Dr. Schwarzschild is a Professor of Neurology at Harvard Medical School and Attending Neurologist at Massachusetts General Hospital. After Parkinson's disease fellowship training at MGH he developed a translational research program focusing on the role of purines — adenosine, caffeine and urate — among environmental and genetic influences in animal models and clinical studies of PD. He has developed and led phase 2/3 clinical trials toward disease-modifying therapy for people with Parkinson’s. At MGH he works with Parkinson's patients and their families in a weekly movement disorders clinic.

HUBERT FERNANDEZ, MD, CO-CHAIR (2018-2024)

Hubert H. Fernandez, MD, is Professor of Neurology at the Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Chair/Director of the Center for Neurological Restoration at Cleveland Clinic in Cleveland, Ohio. He is the holder of the James and Constance Brown Family Endowed Chair in Movement Disorders. He received both his BS in Biology and MD degree from the Philippines. He completed his internship in Internal Medicine at University of Pennsylvania/Pennsylvania Hospital in Philadelphia, Pennsylvania; his residency in Neurology at Boston University Medical Center in Boston, Massachusetts; and his fellowship in Movement Disorders at Brown University in Rhode Island.

Dr Fernandez is an internationally recognized expert in movement disorders who has been voted one of the Best Doctors in America by his peers. After completing his medical training, he joined the faculty of Brown University School of Medicine as Assistant Professor in the Department of Clinical Neurosciences. In 2003, Dr Fernandez relocated to the University of Florida, where he eventually became Director of the Clinical Research Unit for Neurological and Psychiatric Disorders, Vice Chair of Academic Affairs, and Professor of Neurology prior to joining Cleveland Clinic. An active and productive researcher, he has led or participated in over 150 clinical trials and has published his findings in over 300 articles on Parkinson disease, DBS, behavioral and non-motor features of PD, cervical dystonia, blepharospasm, and other movement disorders. He has written a dozen books and has published 50 book chapters. He is currently the Co-Editor-In-Chief of Parkinsonism and Related Disorders, and has served on the editorial board of Movement Disorders and several other peer-reviewed journals.

Dr Fernandez is a fellow of the American Academy of Neurology and the American Neurological Association. He is currently elected for his second term as the Co-Chair of the Parkinson Study and Secretary of the International Association for Parkinsonism and Related Disorders, He served his third term as Co-Medical Editor of the Movement Disorders Society Website, which received the Standard of Excellence Award twice by the Web Marketing Association during his tenure. He has been a Councilor for the AAN Movement Disorders Section, Sectretary of the MDS Pan-American Section, Executive Committee Member of the Parkinson Study Group and Dystonia Study Group and served as the President of the Florida Society of Neurology and World Neurology Foundation. He was awarded the Most Outstanding Alumnus by his medical school in 2008, and the Presidential Distinguished Service Award by the Movement Disorders Society at the 16th International Congress for Parkinson’s Disease and Movement Disorders in Dublin, Ireland in 2012.

CINDY CASACELI (2018-2021)

Ms Casaceli has directed the Clinical Trials Coordination Center (CTCC) for over 10 years with more than 25 years experience in the operational conduct of an academic research organization. She has overseen the conduct and compliance of clinical trials that have led to the FDA approve of seven compounds. She has served as the Administrative PI for 8+ studies including NIH funded SURE-PD3, Michael J. Fox Nilo-PD and FoxBioNet, and PDGENE with the Parkinson Foundation. She holds a BS in Biochemistry, MBA in Computer/Information Systems & Accounting, and a Leadership Coaching Certficiate.

MARIE-HÉLÈNE SAINT-HILAIRE, MD, FRCPC, FAAN (2018-2021)

Dr Marie-Hélène Saint-Hilaire is the Medical Director of the Parkinson’s Disease and Movement Disorders Center at Boston University and Director of the American Parkinson Disease Association Center for Advanced Research at Boston University Medical Campus. She did her medical school at the Universit de Montréal, and her residency at the Montreal Neurological Institute. Dr Saint-Hilaire has done her movement disorder fellowship at the Hôpital de La Salpêtrière in Paris and at Columbia Presbyterian Hospital in New York. She has been a member of the Parkinson Study Group since 1997 and has been the site PI for several PSG clinical research trials. In addition, she has participated in over 100 clinical research studies evaluating new medications, biomarker observational studies, genetic studies, surgical studies, and studies that address self-management rehabilitation and care. She has also been a member of the PSG Scientific Review Committee. As a member of the Executive Committee, she shares her experience with developing and sustaining a clinical trial program highlighting the important synergy that must exist with all members of the research team. This includes understanding the invaluable role of study coordinators, and the need to actively develop new faculty as investigators at clinical sites. It is also essential that research subjects are well cared for and that a center has strong connections to the community they serve.

KAREN WILLIAMS (2018-2021)

Karen is the Sr. Clinical Research Associate at Northwestern University, Parkinson’s Disease & Movement Disorders Center (NUMDC) that is recognized by the Parkinson’s Foundation, Huntington’s disease and Wilson’s Foundations as Centers of Excellence.

Karen has been in the clinical research arena her entire career and has managed, coordinated, and monitored many clinical trials in both Academia and Industry. She serves on several research committees with Northwestern Medicine, as well as outside organizations, providing education, training, and mentoring. Karen’s interest is in providing education and resources for clinical research staff and faculty to help ensure that we provide very valuable and reliable data to our Sponsors. She was also involved with the development of the Chicago Movement Coalition. The Chicago Movement Coalition (CMC) is an alliance of community and academic partners that was established in 2019 to be a resource and advocate for members of the Chicagoland community who are underrepresented in the area of Parkinson’s disease care.

The main goal of the CMC is to empower community members by developing and sustaining educational initiatives about Parkinson’s disease care and research opportunities.

ERIC MACKLIN (2015-2021)

Dr. Macklin is an Assistant in Biostatistics at Massachusetts General Hospital and an Instructor in the Department of Medicine at Harvard Medical School. His research interests focus on neurodegenerative and neurodevelopmental diseases with an emphasis on clinical trial design.

He is an Executive Committee member of the Parkinson Study Group and an academic advisor for the Critical Path for Parkinson's Consortium. He was an organizing member and the lead biostatistician for the Airlie House Clinical Trials Guidelines for ALS research. He is a lead biostatistician for the Healey ALS Center Platform trial, for the phase 3 SURE-PD3 trial in Parkinson disease, and for the Autism Treatment Network. In addition to his work in neurology, he has a long and ongoing interest in evaluation of complementary and alternative medicine, serving as PI or statistician for trials of acupuncture, Tai Chi, and mind-body practices.

JOEL S PERLMUTTER (2020-2023)

Joel S Perlmutter is Head of Movement Disorders and the Elliot Stein Family Professor of Neurology and Professor of Radiology, Neuroscience, Physical Therapy, and Occupational Therapy as well as Director of the American Parkinson Disease Association Advanced Research Center for Parkinson Disease and Director of the Huntington Disease Center of Excellence at Washington University in St. Louis.

BRAD RACETTE (2018-2021)

Dr. Racette is the Robert Allan Finke Professor and Executive Vice Chairman of Neurology at Washington University School of Medicine in St. Louis and an Honorary Professor of Public Health at the University of the Witwatersrand in Johannesburg, South Africa. Currently, he chairs the PSG mentoring committee. He is a graduate of Princeton University, Northwestern University School of Medicine, and completed his neurology residency and fellowship in movement disorders at Washington University School of Medicine. His research focuses on manganese neurotoxicity and environmental risk factors for Parkinson disease. His research is supported by National Institutes of Health, Michael J. Fox Foundation, U.S. Department of Defense, American Parkinson Disease Association, and Cure Alzheimer Foundation. He has led global health research projects for over a decade in South Africa and Finland. His work in South Africa focuses on occupational and environmental manganese with an emphasis on vulnerable populations. He has served as a peer reviewer and advisor for numerous medical journals and international regulatory agencies. He has received numerous awards and has authored over 160 peer reviewed publications.

ANDREW SIDEROWF, MD, MS (2020-2023)

Andrew Siderowf, MD MS is the Hurtig-Stern Professor of Neurology and the Chief of the Movement Disorders Division in the Penn Perelman School of Medicine Department of Neurology. He received his MD from Duke University, completed residency training at the Hospital of the University of Pennsylvania and fellowship training in Movement Disorders and Experimental Therapeutics at the University of Rochester (under Ira Shoulson, MD). His research addresses the organization and conduct of clinical trials, particularly the use of biomarkers as outcome measures

TANYA SIMUNI, MD (2020-2023)

Dr. Simuni graduated with her medical degree from Leningrad Medical School and completed an internship in medicine in Leningrad, Russia. Dr. Simuni joined the faculty of the Northwestern University Feinberg School of Medicine in 2000 to build and lead a multidisciplinary movement disorders center that is recognized by the Parkinson’s Foundation, Huntington Disease Society of America and Wilson’s Foundation as a Center of Excellence and serves as a training model in the region. She is the lead investigator of a number of clinical trials on experimental pharmacology, non-motor manifestations, and pharmacological management of PD. She serves on a number of Steering Committees for the PD national clinical trials, several committees of the Parkinson Study Group and the Parkinson Foundation. She is the Site PI and serve on the Steering Committee for the largest PD biomarker initiative funded by the MJFF (PPMI study). Dr. Simuni is the site PI for the Network for Excellence in Neuroscience Clinical Trials (NEXT) Northwestern Clinical Site (U10). Dr. Simuni is an active member of the American Academy of Neurology, American Neurological Association, the Movement Disorders Society as well as the Parkinson’s Study Group.

Donna Moszkowicz
Jeanne Paiko
Sarah Sperling
Cindy Wan

Scientific Review Committee

The Scientific Review Committee will review all PSG research proposals including retrospective data mining projects and prospective studies, whether observational or interventional. A primary and secondary reviewer will be assigned and the Committee will review and score each proposal. The Committee will also facilitate contacts with the Mentoring Committee as appropriate. Requests for use of PSG repositories (DNA, CSF, blood, urine, video) will also be reviewed by the Scientific Review Committee. The Scientific Review Committee will consist of a chair and approximately ten to fifteen members to serve terms of three years and will rotate off one third of its members every year.

Prior to submitting any proposal to the PSG, we encourage all investigators to make use of the PSG Working Groups and get assistance, if needed, from the PSG Mentoring Committee.

Note: For projects requiring access to the DATATOP biospecimen repository, a separate proposal review and funding mechanism is now managed through NINDS at https://pdbp.ninds.nih.gov/pd-brac .

  1. Proposal is submitted to PSG and reviewed by PSG Chair and Co-chair
  2. Proposal is assigned a primary and secondary reviewer from the Scientific Review Committee (SRC)
  3. Primary and secondary reviewers submit their review within 30 days of receipt
  4. Proposal and reviews are distributed to the SRC
  5. SRC rates the proposal using the NIH 9-point scoring system. Individual reviewer scores will be averaged and the result multiplied by 10 to determine the final impact/priority score (range of 10 to 90)
  6. Proposal is approved, approved with criticisms, or not approved
  7. Proposals with criticisms are referred to the PSG Executive Committee

Submissions due 30 days before SRC meeting and responses back to proposing investigator within 30 days of SRC meeting. SRC meets 3 times per year, every 4 months.

Upcoming Submission Deadlines:

  • May 3, 2021
  • August 2, 2021
  • December 6, 2021

Click here to download the RFP.

NeuroNEXT provides an established infrastructure including a data coordinating center (University of Iowa), Clinical Coordinating Center (Massachusetts General Hospital) and approximately 28 study sites. Funded NeuroNEXT studies will use this infrastructure which includes central IRB and pre-established contractual agreements with all sites. All but 3 NeuroNEXT sites are also Parkinson Study Group sites.

Academics, foundations and industry are eligible to submit proposals to NeuroNEXT. Initially, a brief Study Concept Synopsis is evaluated for mission relevance and feasibility by the NeuroNEXT Executive Committee (NEC). Proposals which are found to be mission relevant, feasible and of sufficient priority are referred to protocol working groups for development of grant applications. The resulting grant application would be submitted for NINDS peer review.

Find the NeuroNEXT Clinical Study Concept Synopsis here: http://www.neuronext.org/

Utilizing DATATOP Biospecimens

PSG DATATOP biospecimens research: Projects requiring access to the DATATOP biospecimen repository a separate proposal review and funding mechanism has been developed in collaboration with The Michael J. Fox Foundation (MJFF) and the NINDS Parkinson’s Disease Biomarkers Program (PDBP) and supports the identification and validation of novel biomarkers through use of DATATOP biospecimens.

The Michael J. Fox Foundation is now accepting pre-proposals to our Use of Parkinson’s Disease Biosamples Request for Applications (RFA).

Awards are up to $300,000 for a one- to two-year grant. The deadline for pre-proposals is September 24, 2019, at 5 p.m. ET. Awards include funding and accompanying biosamples for research programs focusing on Parkinson’s target and assay development. The Foundation is especially interested in studies focused on:

  • Assay development and validation for novel biomarkers
  • Biomarker replication and validation of promising measures that associate with Parkinson’s or progression
  • Target discovery and validation

Apply Now.

 

Who Serves on the PSG SRC?

Download a PDF of the member list here. 

Joel Perlmutter, MD, Chair (2020-2023)
Washington University School of Medicine
Department of Neurology
660 South Euclid Box 8111
St Louis, MO 63110
(314) 362-6026     Fax: (314) 362-0168
Email: joel@npg.wustl.edu
Assistant: Enid McIntosh enidmcintosh@wustl.edu

M. Maral Mouradian, MD, Co-Chair (2020-2023)
William Dow Lovett Professor of Neurology
Vice Chancellor for Faculty Development, Rutgers Biomedical and Health Sciences
Director, RWJMS Institute for Neurological Therapeutics
Rutgers – Robert Wood Johnson Medical School
Director, American Parkinson Disease Association Center for Advanced Research
683 Hoes Lane West, Room 180
Piscataway, NJ 08854
(732) 235-4772     (732) 235-4773     Fax: (248) 325-3115
Email: m.mouradian@rutgers.edu
Executive Assistant: Lauren Kelly lk496@rwjms.rutgers.edu

Christopher A. Beck, PhD (2019-2022)
Associate Professor
Department of Biostatistics & Computational Biology
University of Rochester Medical Center
601 Elmwood Avenue, Box 630
Rochester, NY 14642
(585) 275-6781     Fax: (585) 273-1031
Email: christopher_beck@urmc.rochester.edu
Download Dr. Beck’s bio here.

Jia Li, PhD (2019-2022)
Department of Public Health Sciences
Henry Ford Health System
One Ford Place, 3E
Detroit, MI 48168
Email: jli4@hfhs.org
Download Dr. Li’s bio here.

Jennifer G. Goldman, MD, MS (2020-2023)
Section Chief, Parkinson’s Disease and Movement Disorders, Shirley Ryan Abilitylab
Professor, Department of Physical Medicine & Rehabilitation and Neurology, Northwestern University Feinberg School of Medicine
355 E. Erie Street
Chicago, IL 60611
(312) 238-1000     Fax: (312) 238-3695
Email: jennifer.goldman@northwestern.edu

Alberto Espay, MD, MSc (2020-2023)
Professor of Neurology, Director, Gardner Family Center
Research Chair for Parkinson’s Disease and Movement Disorders
University of Cincinnati
260 Stetson St., Suite 2300
Cincinnati, OH 45267-0525
(513) 558-4035     Fax: (513) 558-7015
Email: Alberto.espay@uc.edu
Assistant: Lori Selm lori.selm@uc.edu

Jill L. Ostrem, MD (2020-2023)
Carlin & Ellen Wiegner Endowed Professor of Neurology
Division Chief, UCSF Movement Disorder and Neuromodulation Center
Weill Institute for Neurosciences
University of California San Francisco
1635 Divisadero Street, Suite 520
San Francisco, CA 94143
(415) 514-6966     Fax: (415) 353-9060
Email: Jill.Ostrem@ucsf.edu

Joseph Savitt, PhD (2018-2021)
University of Maryland School of Medicine
Associate Professor of Neurology
110 S. Paca Street, 3rd Floor
Baltimore, Maryland 21201
(410) 328-7809     Fax: (410) 328-0167
Email: JSavitt@som.umaryland.edu
Download Dr. Savitt’s bio here.

Tatiana Foroud, PhD (2020-2023)
Chair, Department of Medical & Molecular Genetics
Department of Medical and Molecular Genetics
Indiana University School of Medicine
410 W. 10th Street | HS 4000
Indianapolis, IN 46202-3002
(317) 274-2240     Fax: (317) 278-1100
Email: tforoud@iu.edu
Assisttant: Linda Robinson robinlir@iu.edu

Marta San Luciano Palenzuela, MD (2018-2021)
University of California, San Francisco
1635 Divisadero Street, Suite 520
San Francisco, CA 94115
(415) 353-2311     Fax: (415) 353-9060
Email: Marta.SanLucianoPalenzuela@ucsf.edu
Download Dr. San Luciano’s bio here.

Gregory Pontone, MD, MHS (2018-2021)
Director, Parkinson’s Neuropsychiatry Clinical Programs
Johns Hopkins University School of Medicine
Morris K. Udall Parkinson’s Disease Research Center
Associate Professor, Departments of Psychiatry and Neurology
(410) 502-0477
Email: gpontone@jhmi.edu
Download Dr. Pontone’s bio here.

Membership

PSG membership shall consist of five distinct but not mutually exclusive categories: 1) Credentialed Members, 2) Committee Members, 3) Working Group Members, 4) Coordinator Members, and 5) Associate Members.

  • 1) Credentialed Members are individuals who have completed the PSG credentialing process and have been granted full approval, provisional approval, or study-specific approval.

  • 2) Committee Members are individuals who have been actively serving on the Executive Committee (EC) or a standing committee or have served in previous years.

  • 3) Working Group Members are individuals who have been actively participating in meetings, projects, and ongoing research of a working group.

  • 4) Coordinator Members are individuals who work at a PSG credentialed site and are currently working or have previously worked on a PSG trial

  • 5) Associate Members shall include: 1) consultants who are actively serving on standing, advisory, or monitoring committees, 2) professional staff at a coordination, biostatistical center, and at sites supporting active* PSG studies 3) investigators who received “study-specific” credentialing for active PSG studies, and 4) affiliates (including from foundations, government, and industry)

*Active PSG studies are those, for which 1) the primary manuscript has not yet been published, and 2) 2 years have not passed since the primary study completion date. Upon publication of the primary manuscript a study is then no longer considered “active.”

Voting Members shall include: Categories 1-4 as stated above

Credentialed members with study-specific approval, associate members, and working group members who are not fully credentialed are not eligible to vote.

Each voting member shall have one vote. Votes are not transferable and cannot be cast by proxy in instances when the presence of the voting member is required.

HOW DO YOU BECOME A MEMBER?

  • 1) Credentialed Members – For information on how to become a credentialed member, please refer to our Credentialing tab

  • 2) Committee Members – Committee members are selected or nominated by their peers to serve in these roles

  • 3) Working Group Members – To become a member of a working group please refer to our list of working groups listed on the site. Once you decide on a working group to join, email the chair or co-chair directly to request to be added to the group. They will then approve your membership and officially have you added to the roster.

  • 4) Coordinator Members – Coordinators are can become members either by requesting to join via an email to the PSG Administrative Director or by working at a site that is participating in a PSG study

  • 5) Associate Members – Associate members are added to the PSG database via the administrative team. If you would like to inquire about your membership status, please contact Donna Moszkowicz.

 

Publications & Newsletters

Journal Articles, Letters, Book Chapters, Abstracts, Ancillary Studies & PSG Symposium:

Parkinson Study Group Publications and Abstracts (updated August 2020)

PSG Authorship and Publication Policy

publications

PSG Mentorship Program

PSG Visiting Mentorship Program

The PSG Visiting Mentorship Program is funded by a grant from Sunovion Pharmaceuticals. The goal of this program is to promote the continued development of newly trained movement disorders clinician-researchers into world-class investigators. This initiative focuses on the mentorship of young investigators committed to clinical research in the Parkinson arena by seasoned, established clinical investigators. While there are several courses and conference that a young investigator can participate in, there is no substitute for a personal mentor-mentee relationship, where the mentor can review the mentee’s proposed initiative(s), and meet with the mentee’s team, local set up, and provide in-person sage advice.

Available funds: PSG will award up to four awards totaling $7,450, including $5,000 for mentor honorarium and $2,450 for travel, meals, and incidentals related to mentoring.

The Project:

  • Project period is 1 year beginning July 1, 2021 and ending June 30, 2022.

  • Needs to be an investigation into an aspect of PD.

  • The investigators/research can be basic, translational, or clinical.

  • The short and long-term goals of the project should be clearly stated.

  • The reason(s) why a visiting mentorship is critical to the project should be described.

An electronic copy of the proposal in pdf-format must be received by the PSG on or before Friday, June 4, 2021. Applications should be sent by to email to Sarah Sperling.

Mentoring Committee

WHAT IS THE PSG MENTORING COMMITTEE (MC)?

The PSG Mentoring Committee (MC) has three main roles.

1. To solicit, review, and select candidates to receive the Parkinson’s Disease Foundation supported mentored clinical research award. This is a major award in support of a project that is a practical training ground for individuals to acquire new skills and expertise in clinical research.

1. To serve as a resource for individuals who need assistance in formulating and developing protocols to the point where they are ready for review by the Scientific Review Committee.

1. To develop and organize innovative programs to promote interest in Parkinson’s disease research, facilitate the development of mentorship relationships, and increase awareness of resources within the PSG that can provide opportunities for initiating research efforts.

The Mentoring Committee oversees the PSG Advisor Program. Implemented in 2009, the PSG Advisor Program helps new investigators find a local mentor or specific research funding sources for their research.

Download a PDF of the member list here.


Brad A. Racette, MD, Chair (2018-2021)
Washington University School of Medicine
Department of Neurology
660 South Euclid Avenue Campus Box 8111
St Louis, MO 63110
(314) 362-8548 Fax: (314) 747-8289
racetteb@neuro.wustl.edu
Assistant: Tracey Erdman – erdmant@neuro.wustl.edu

James Leverenz, MD, Co-Chair (2018-2021)
Director, Cleveland Lou Ruvo Center for Brain Health
Dr. Joseph Hahn Endowed Chair of Neurological Sciences
Cleveland Clinic
9500 Euclid Avenue, U10
Cleveland, OH 44195
(216) 636-4044
leverej@ccf.org
Assistant: Shelley Sekerak – sekeras2@ccf.org

Roy Alcalay, MD, MSc (2019-2022)
Columbia University
710 W. 168th Street
New York, NY 10032
rna2104@cumc.columbia.edu

John L. Goudreau, DO, PhD (2018-2021)
Director, Translational Neurobiology Research Unit Director, Movement Disorders Clinic Associate
Professor Department of Neurology Department of Pharmacology & Toxicology
B407 Clinical Center
Michigan State University
East Lansing, MI 48824
(517) 432-9277 Fax: (517)-432-9414
john.goudreau@ht.msu.edu
Assistant: Krista Leiter: Krista.Leiter@hc.msu.edu

Ali G. Hamedani, MD, MHS (2019-2022)
Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania
Philadelphia, PA 19107
Ali.Hamedani@pennmedicine.upenn.edu
Download Dr. Hamedani’s bio here.

Emily Hill, MD (2018-2021)
Baylor College of Medicine
7200 Cambridge, 9A
Houston, TX 77030
emily.j.hill8@gmail.com
Download Dr. Hill’s bio here.

Lan Luo, MD, MS (2020-2023)
Beth Israel Deaconess Medical Center/
Harvard Medical School
Department of Neurology
330 Brookline Ave., KS220
Boston, MA 02215
(617) 667-1337 Fax: (617) 975-5454
lluo2@bidmc.harvard.edu
Download Dr. Luo’s bio here.

Michael McDermott, PhD
University of Rochester
Department of Biostatistics
601 Elmwood Avenue Box 630
Rochester, NY 14642
(585)275-6685 Fax: (585)273-1031
mikem@bst.rochester.edu
Download Dr. McDermott’s bio here.

Delaram Safarpour, MD, MSCE (2019-2022)
Assistant Professor of Neurology
Co-Director of DBS Program
OHSU Parkinson Center & Movement Disorders Program
Portland, Oregon 97239
safarpou@ohsu.edu
Download Dr. Safarpour’s bio here.

Allison Willis, MD (2019-2022)
Pennsylvania Hospital
330 S. 9th Street
Philadelphia, PA 19107
(215) 829-6500 Fax: (215) 829-7724
allison.willis@uphs.upenn.edu

Mentored Clinical Research Award

AWARD OVERVIEW

The PSG MCRA is for new investigators in patient-oriented research in Parkinson’s disease and related disorders.

The Mentored Clinical Research Award (MCRA) for new investigators is funded by a grant from the Parkinson’s Foundation (PF) to the Parkinson Study Group (PSG). The PF collaborates with the PSG to encourage the professional and scientific development of young investigators on their path to independence. To this end, this grant supports a new investigator for a one year project in patient oriented research in Parkinson disease (PD) or other parkinsonian disorders. The new investigator works under the mentorship of an experienced investigator. Training should enhance the junior clinical research skills. The research plan should address unmet needs of people living with PD, have the potential for broad application among the PD community, and lead to advances in clinically relevant treatment options.

Award Timeline: Closed for 2020.
Congratulations to our selected recipient, Dr. Lan Luo! The Mentoring Committee was very favorably impressed by her proposal, “Understanding Neural Networks of Freezing of Gait.”

PSG International Collaborators

Karl Kieburtz, PI

A two-day in-person meeting was held last January, 2012, in New Delhi, India, to introduce the groups in person and to begin training efforts, and another in-person meeting was held on February 8-9, 2013, in New Delhi.

A couple small projects developed by the group at the January meeting have already been completed. Also, many of the aims of the grant have been accomplished, including training of the Indian investigators of PRAI on the MDS-UPDRS and training on the Unified Dyskinesia Rating Scale has begun. Also the PRAI investigators have completed training on the eClinical electronic data capture system. Additionally all of the PRAI investigators who were in attendance at last year’s in-person meeting have now become members of The Movement Disorders Society (MDS), which facilitated their training on the MDS-UPDRS, and will help facilitate training on the UDysRS as well. An additional project idea developed by the group at last year’s in-person meeting was the translation of the MDS-UPDRS into Indian dialects, such as Hindi, Marathi and Bengali. The India PI Dr. Behari and her colleagues have already translated the MDS-UPDRS into Hindi. One of the other projects developed was to assess the agreement between investigators when rating individual patients, as an assessment of the quality of the examinations, which has been operationalized as a comparison between senior and junior raters of the MDS-UPDRS. This project has already begun in the US and the protocol is under review by the India sites to submit to their local IRBs. This small inter-rater reliability project is especially useful for the goals of the CPPD, as it utilizes several aims of the project, including recent training on PD scales, use of the eClinical system, and overall collaboration between US and India.

Despite some initial difficulties with the India government’s release of funding to the India PI, this project is moving along. This grant is a two-year R21 grant from NIH.

International Colleagues

Karl Kieburtz, PI

A two-day in-person meeting was held last January, 2012, in New Delhi, India, to introduce the groups in person and to begin training efforts, and another in-person meeting was held on February 8-9, 2013, in New Delhi.

A couple small projects developed by the group at the January meeting have already been completed. Also, many of the aims of the grant have been accomplished, including training of the Indian investigators of PRAI on the MDS-UPDRS and training on the Unified Dyskinesia Rating Scale has begun. Also the PRAI investigators have completed training on the eClinical electronic data capture system. Additionally all of the PRAI investigators who were in attendance at last year’s in-person meeting have now become members of The Movement Disorders Society (MDS), which facilitated their training on the MDS-UPDRS, and will help facilitate training on the UDysRS as well. An additional project idea developed by the group at last year’s in-person meeting was the translation of the MDS-UPDRS into Indian dialects, such as Hindi, Marathi and Bengali. The India PI Dr. Behari and her colleagues have already translated the MDS-UPDRS into Hindi. One of the other projects developed was to assess the agreement between investigators when rating individual patients, as an assessment of the quality of the examinations, which has been operationalized as a comparison between senior and junior raters of the MDS-UPDRS. This project has already begun in the US and the protocol is under review by the India sites to submit to their local IRBs. This small inter-rater reliability project is especially useful for the goals of the CPPD, as it utilizes several aims of the project, including recent training on PD scales, use of the eClinical system, and overall collaboration between US and India.

Despite some initial difficulties with the India government’s release of funding to the India PI, this project is moving along. This grant is a two-year R21 grant from NIH.

Beijing Institute of Geriatrics and Department of Neurology

Jennifer Zheng is a senior statistician in Beijing Institute of Geriatrics, Xuanwu Hospital, Capital Medical University. She got her master degree in Biostatistics from University of South Florida in 2002 and has been working on clinical research in both academic and industry settings. Before joined Xuanwu Hospital, she had been worked for Florida Mental Health Institute, Beth Israel Deaconess Medical Center and Sanofi-Aventis as a SAS programmer and biostatistician for more eight years. She has published and finished statistical analysis for more than ten international clinical trials and several large-scale epidemiology studies.

Professor for Neurology and Director of the Department of Neurology, The Philipps University, Marburg, Germany

Dr. Oertel obtained his MD at the University of Berlin, Germany. He completed his postgraduate neuroscience training at the Laboratory of Clinical Sciences at the National Institute of Mental Health, NIH, Bethesda, Maryland, USA. He is full professor for neurology and director of the Department of Neurology at the Philipps University Marburg, Germany, a Centre of Excellence of the US National Parkinson Foundation. Wolfgang H. Oertel is currently speaker of the Competence Network on Parkinson’s Disease (an outstanding infrastructure for medical research in Germany) and chairman of the German Parkinson Study Group. Since 2011 he is president of the German Society of Neurology and liaison professor of the German National Academic Foundation at the Philipps-University of Marburg. He received the Parkinson-Frosst Award (1986) and the Dingebaur-Price for Parkinson research (2004) from the German Society of Neurology and the “carrier award for basal ganglia disorders” from the German Research Foundation (1987-1990).

Dr. Oertel’s research interests focus on the diagnosis and treatment of neurodegenerative disorders (particularly Parkinson’s disease and atypical parkinsonian syndromes) as well as sleep disorders (especially REM-sleep-behaviour-disorder and restless-legs-syndrome). He has profound expertise in the design and conduct of diagnostic and therapeutical trials in these fields and has been principal investigator or co-principal investigator in numerous clinical trials.

Representing PRAI (Parkinson Research Alliance of India)

Kapil Dev Sethi, MD, FRCP is Professor of Neurology at the Medical College of Georgia, Augusta, Georgia. He also serves as the Director of the Movement Disorders Center at MCG. Dr. Sethi is board certified in Neurology and Internal medicine.

Dr. Sethi earned his medical degree at the Christian Medical College, Ludhiana, India. After completing his residency in Internal Medicine and Neurology at the Post Graduate Institute of Medical Education and Research, Chandigarh, India, he finished a research fellowship Charing Cross Group of Hospitals and Medical School, London, UK. He was a Registrar in Neurology at the Welsh National School of Medicine at Morriston Hospital, and served a Neurology residency at the Medical College of Georgia.

An author of numerous reviews, abstracts, book chapters, and journal articles, Dr. Sethi’s work has been published in peer-reviewed publications, including Neurology, Movement Disorders and Annals of Neurology. He serves as an Associate Editor for Movement Disorders and has served as a section editor for Current Neurology and Neurosciences Reviews and Medscape Neurology.

Dr. Sethi is a Fellow of the American Academy of Neurology and the Royal College of Physicians (London). He is the Vice President of the Tremor Research Group. He is a member of the PSG, American Neurological Association, the Movement Disorder Society, and the American Association of Physicians from India. He has served on the International Executive committee for the Movement Disorders Society and on the board of Directors of the AAN and has served as a Treasurer of the AANF. He also serves as the Chair of the Development Committee of the MDS and is the MDS appointee on the WHO advisory group for the revision of ICD-10.

With research interests in Parkinson’s disease, restless legs syndrome, and cervical dystonia, Dr. Sethi has participated as principal investigator in numerous clinical trials. He is a frequent invited lecturer and has held visiting professorships at Duke University, Emory University and MGH Boston, among others.

Swedish Parkinson Research Network, SWEPAR-net

Dr. Bergquist earned his medical degree in 1997at the University of Gothenburg, Sweden and went on to earn a PhD in pharmacology in 2002 at the University of Gothenburg. He did a postdoctoral fellowship at the University of Edinburgh from 2004-2008. Worked with Profs Dutia, Ludwig and Leng studying brain stem synaptic plasticity and mechanisms of neuropeptide release and function.

Currently, Dr. Bergquist is the Neurology registrar at Sahlgrenska University Hospital in Gothenburg and holds a Junior Research Position on a personal grant from the Swedish Research Council. He is a Board member of the recently formed Swedish Parkinson Research Network, SWEPAR-net. SWEPAR-net is a subordinate to the Swedish Movement Disorder Society and aims to stimulate preclinical, clinical and translational PD related research in Sweden.

Dr. Bergquist has a translational research profile encompassing Parkinson disease animal models, behavior and in vivo neurochemistry, in vivo physiology and clinical patophysiology. His PhD thesis described the downstream permissive role of nigral somatodendritic dopamine release for motor functions, and he has since then also worked with models of brain stem synaptic plasticity and its role in posture and balance. Recent projects concern deficits in spatial memory strategies in PD patients and the role of sensory noise for motor-, and cognitive function in the dopamine depleted brain, and in Parkinson’s disease in particular.

Selected publications:

Andersson D., Nissbrandt H. and Bergquist F. (2006). ”Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission” Eur J Neurosci 24:617-624.

Brederlau A., Correia A.S., Anisimov S.V., Elmi M., Paul G., Roybon L., Morizane A., Bergquist F., Riebe I., Nannmark U., Carta M., Hanse E., Takahashi J., Sasai Y., Funa K., Brundin P., Eriksson P.S .& Li J.Y. (2006). Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson’s disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 24, 1433-1440.

Bergquist, F., Ruthven, A., Ludwig, M. and Dutia, M.B (2006). “Histaminergic and glycinergic modulation of GABA release in the vestibular nuclei of normal and labyrinthectomised rats”, J Physiol, 577:857-868.

Bergquist, F., Ludwig, M. and Dutia, M.B (2008). “Role of the commissural inhibitory system in vestibular compensation in the rat”, J Physiol, 586:4441-4452.

Andersson, D.R., Björnsson, E., Bergquist F. and Nissbrandt H. (2009) “Motor activity-induced dopamine release in the substantia nigra is regulated by muscarinic receptors”, Exp Neurology, 221:251-259.

Pålsson E, Söderlund G, Klamer D, Bergquist F. (2010) Noise benefit in prepulse inhibition of the acoustic startle reflex. Psychopharmacology (Berl) pre-print online publication. DOI: 10.1007/s00213-010-2074-6.